Bevacizumab in the treatment of patients with advanced breast cancer: Where have we landed?

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 5, 2010, Pages 331-342

  Dirix, L Y ^a   Van Dam, P A ^b   Prove, A M ^b   Vermeulen, P B ^b  

^a SINT AUGUSTINUS HOSPITAL   (Belgium)

^b Cancer Center   (Belgium)

Author keywords

advanced breast cancer; bevacizumab; chemotherapy; vascular endothelial growth factor

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; HYPERTENSION; JAW OSTEONECROSIS; LOW DRUG DOSE; NAUSEA AND VOMITING; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 78649287450     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010376301     Document Type: Review

References (75)

1. Baar, J., Silverman, P., Lyons, J., Fu, P., Abdul-Karim, F., Ziats, N. et al. (2009) A vasculature-targeting regimen of preoperative docetaxel with or withot bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 15: 3583-3590.
2. Benoy, I.H., Salgado, R., Elst, H., van Dam, P., Weyler, J., van Marck, E. et al. (2005) Relative microvessel artea of the primary tumor, and not lymph node status predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res 7: R210-R219.
3. Bhargava, P. (2009) VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Reg Integr Comp Physiol 297: R1-R5.
4. Bluff, J.E., Menakuru, S.R., Cross, S.S., Higham, S.E., Balasubramanian, S.P., Brozwn, N.J. et al. (2009) Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer 101: 666-672.
5. Borre, M., Offersen, B.V., Nerstrom, B. and Overgaard, J. ( 1998) Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 78: 940-944.
6. Burstein, H.J., Chen, Y.H., Parker, L.M., Savoie, J., Younger, J., Kuter, I. et al. (2008) VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14: 7871-7877.
7. Burstein, H.J., Spigel, D., Kindsvogel, K., Parker, L.M., Bunnel, C.A., Partridge, A.H. et al. (2005) Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II trial. Breast Cancer Res Treat 94(Suppl. 1): S6 (Abstract 4).
8. Calleri, A., Bono, A., Bagnardi, V., Quarna, P., Mancuso, P., Rabascio, C. et al. (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15: 7652-7657.
9. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M. et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
10. Chamberlain, M.C. ( 2005) Neoplastic meningitis. J Clin Oncol 15: 3605-3613.
11. Cobleigh, M.A., Langmuir, V.K., Sledge, G.W., Miller, K.D., Haney, L., Novotny, W.F. et al. (2003) A phase I / II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem Oncol 30: 117-124.
12. Conlin, A.K., Hudis, C.A., Bach, A., Moynahan, M., Lake, D., Forero-Torres, A. et al. (2009) Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer. J Clin Oncol 27: 42s (Abstract 1006).
13. Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R. et al. (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26: 4899-4905.
14. Dhakal, H.P., Naume, B., Synnestvedt, M., Borgen, E., Kaaresen, R. and Schlichting, E. ( 2008) Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination. Clin Cancer Res 14: 2341-2350.
15. Dirix, L.Y., Romieu, G., Provencher, L., Grimes, D., de Souza Viana, L., Paterson, A. et al. (2009) Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. Cancer Res 69(Suppl.): 292s (Abstract #4116).
16. Dirix, L.Y., Vermeulen, P.B., de Wever, I. and van Oosterom, A.T. ( 1997) Soft tissue sarcoma in adults. Curr Opin Oncol 9: 348-359.
17. Dome, B., Hendrix, M.J.C., Paku, S., Tovari, J. and Timar, J. ( 2007) Alternative vascularization mechanisms in cancer. Am J Pathol 170: 1-15.
18. Eremina, V., Jefferson, J.A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J. et al. (2008) VEGF inhibition and renal thrombotic microangiopathy. N Eng J Med 358: 1129-1136.
19. Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N. et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal disease. J Clin Invest 111: 707-716.
20. Ferrara, N. ( 2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29: 789-791.
21. Ferrara, N. ( 2010) Pathways mediating VEGF-independent tumor angiogenesis. Cyto Growth Fact Rev 21: 21-26.
22. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S. et al. (2006) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
23. Ferrara, N. and Davis-Smith, T. ( 1997) The biology of vascular endothelial growth factor. Endocrine Rev 18: 4-25.
24. Finkenzeller, G., Wendel, K., Zimmermann, W., Westin, G. and Marmé, D. ( 2004) Activated Neu/ ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp1. Angiogenesis 7: 59-68.
25. Foekens, J.A., Peters, H.A., Grebenchtchiklov, N., Look, M.F., Meijer-Van Gelder, M.E., Geerts-Moespot, A. et al. (2001) High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61: 5407-5414.
26. Forero, A., Saleh, M., Galleshaw, J., Jones, C., Shah, J., Percent, I. et al. (2009) A pilot trial of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and / or progesterone receptor positive breast cancer. Cancer Res 69(Suppl.): 24s (Abstract #1088).
27. Frangié, C., Lefaucheur, C., Medioni, J., Jacquot, C., Hill, G.S. and Nochy, D. ( 2007) Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 8: 177-178.
28. García-Sáenz, J.A., Martín, M., Calles, A., Bueno, C., Rodriguez, L., Bobokova, J. et al. (2008) Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother 20: 632-639.
29. Gordon, M.S., Margolin, K., Talpaz, M., Sledge, G.W., Holmgren, E., Benjamin, R. et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843-850.
30. Guardino, A.E., Chen, M., Levy, M. and Chen, M. ( 2009) Phase II trial with gemcitabine, paclitaxel and bevacizumab for the first-line treatment of metastatic breast cancer. Cancer Res 69: 853s (Abstract 6089).
31. Guarneri, V., Miles, D., Robert, N.J., Dieras, V.C., Glaspy, J., Smith, I.E. et al. (2009) Analysis of bevacizumab (Bev) therapy, bisphosphonate use and osteonecrosis of the jaw (ONJ) in >1900 patients treated in two randomized, controlled trials. Cancer Res 69(Suppl.): 512s (Abstract #208).
32. Guidi, A.J., Schnitt, S.J., Fisher, L., Tognazzi, K., Harris, J.R., Dvorak, H.F. et al. (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80: 1945-1954.
33. Herrlinger, U., Wiendl, H., Renninger, M., Förschler, H., Dichgans, J. and Weller, M. ( 2004) Vascular endothelial growth factor in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 91: 219-224.
34. Hurvitz, S.A., Pegram, M.D., Lin, L.-S., Chan, D.S., Allen, H.J., Dichmann, R.A. et al. (2009) Final results of a Phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 24(Suppl.): 854s (Abstract #6094).
35. Hyder, S.M. ( 2006) Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocrine-related Cancer 13: 667-687.
36. Hyder, S.M., Nawaz, Z., Chiapetta, C. and Stancel, G.M. ( 2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60: 3183-3190.
37. Izzidine, H., Brocheriou, I., Deray, G. and Rixe, O. ( 2007) Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 24: 682-685.
38. Jensen, H.M., Chen, I., Devault, M.R. and Lewis, A.E. ( 1982) Angiogenesis induced by normal human breast tissue: a probable marker for precancer. Science 218: 293-295.
39. Kamba, T. and McDonald, D.M. ( 2007) Mechanisms of adverse effects of anti-VEGF therapy in cancer. Br J Cancer 96: 1788-1795.
40. Kowanetz, M. and Ferrara, N. ( 2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022.
41. Laugner, E., Taghavi, P., Chiles, K., Mahon, P.C. and Semenza, G.L. ( 2001) HER 2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
42. Liang, Y., Brekken, R.A. and Hyder, S.M. ( 2006) Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocrine-Related Cancer 13: 905-919.
43. Lin, E.Y. and Pollard, J.W. ( 2007) Tumor associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67: 5064-5066.
44. Linderholm, B., Andersson, J., Lindh, B., Beckman, L., Erlanson, M., Edin, K. et al. (2004) Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic therapy. Eur J Cancer 40: 33-42.
45. Linderholm, B., Tavelin, B., Grankvist, K. and Henriksson, R. ( 1998) Vascular endothelial growth factor is of high prognostic significance in node negative breast carcinoma. J Clin Oncol 16: 3121-3128.
46. Lohela, M., Bry, M., Tammela, T. and Alitalo, K. (2009) VEGFs and receptors in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165.
47. Makhoul, I., Vicki, K.S., Korourian, S., Henry-Tillman, R.S., Siegel, E.R., Westbrook, K.C. et al. (2009) Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer. Cancer Res 69(Suppl.): 343s (Abstract #5114).
48. Margolin, K., Gordon, M.S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G. et al. (2001) Phase Ib trial of intravenous recombinant growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19: 851-856.
49. Masood, R., Cal, J., Zheng, T., Smith, D.L., Hinton, D.R. and Gill, P.S. ( 2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98: 1904-1913.
50. Mayer, E.L., Kozloff, M., Qamar, R., Klencke, B., Balkissoon, J., Parmar, H. et al. (2009) SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib with paclitaxel + bevacizumab as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results. Cancer Res 69(Suppl.): 245s (Abstract #3126).
51. Miles, D., Chan, A., Dirix, L.Y., Cortés, J., Pivot, X., Piotr Tomczak, P. et al. (2010) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol, DOI: 10.1200/JCO.2008.21.6457.
52. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcon, P.K., Fehrenbach, L. et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab and capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799.
53. Miller, K.D., O'Neill, A., Perez, E.A., Seidman, A.D. and Sledge, G.W. ( 2007a) Phase II feasibility trial incorporating bevacizumab into dose dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). Breast Cancer Res Treat 106(Suppl. 1): S147 (Abstract 3063).
54. Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A. et al. (2007 b) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
55. Perez, E.A., Hillman, D.W., Dentchev, T., Le-Lindqwister, N.A., Geeraerts, L.H., Fitch, T.R. et al. (2010) North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 21: 269-274.
56. Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E. and Folkman, J. ( 1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150: 815-821.
57. Presta, L.G., Chen, H., O'Connor, S.J., Chisholm, V., Meng, Y.G., Krummen, L. et al. (1997) Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Can Res 57: 4593-4599.
58. Ramaswamy, B., Elias, A.D., Kelbick, N.T., Dodley, A., Morrow, M., Hauger, M. et al. (2006) Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 12: 3124-3129.
59. Robert, N., Dieras, V., Glaspy, J., Brufsky, A., Bondarenko, I.N., Lipatov, O. et al. (2009) Clinical benefit rate and time to response in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab(b) for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Cancer Res 69(Suppl.): 851s(Abstract #6085).
60. Rochlitz, C., von Moos, R., Mannhart-Harms, M., Winterhalder, R., Rauch, D., Müller, A. et al. (2009) Pegylated liposomal doxorubicin and bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Eur J Cancer Suppl 7: 266 (Abstract 5019).
61. Ryan, P.D., Tung, N.M., Isakoff, S.J., Golshan, M., Richardson, A., Corben, A.D. et al. (2009) Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 27(Suppl.): 18s (Abstract 551).
62. Ryden, L., Jirstrom, K., Bendahl, P.-A., Ferno, M., Nordenskjold, B. et al. (2005) Tumor-specific expression of vascular endothelial growth factor 2 but not vascular endothelial growth factor or human vascular endothelial growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23: 4695-4704.
63. Smith, I.E., Biganzoli, L., Cortes-Funes, H., Stroyakovskiy, D., Franke, F.A., Chlistalla, A. et al. (2009) Primary analysis of study MO19391, a 2000-patient open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent or metastatic breast cancer. Cancer Res 69(Suppl.): 292s (Abstract #4118).
64. Tan, W.W., Dueck, A.C., Flynn, P., Steen, P., Anderson, D., Rowland, K. et al. (2009) Phase II Trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group Trial. Cancer Res 69(Suppl.): 738s (Abstract #4096).
65. Toi, M., Matumoto, T. and Bando, H. ( 2001) Vascular endothelial growth factor: its prognostic, predictive and therapeutic implications. Lancet Oncol 2: 667-673.
66. Traina, T.A., Rugo, H.S., Caravelli, J.F., Patil, S., Yeh, B., Melisko, M.E. et al. (2010) Feasibility of Letrozole with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 28: 628-633.
67. Trinh, B., van Dam, P., Prové, A., Maes, H., van Laere, S., Tjalma, W. et al. (2009) Angiogenic escape and tumour progression in two patients with metastatic breast cancer receiving bevacizumab treatment. Cancer Res 69(Suppl.): 112s (Abstract #1029).
68. Vermeulen, P.B., Colpaert, C., Salgado, R., Royers, R., Hellemans, H., van den Heuvel, E. et al. (2001) Liver metastases from colorectal adenocarcinoma grow in three patterns with different angiogenesis and desmoplasia. J Pathol 195: 336-342.
69. Vermeulen, P.B., Gasparini, G., Fox, S.B., Colpaert, C., Marson, L.P., Gion, M. et al. (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38: 1564-1579.
70. Wang, Y., Fei, D., Vanderlaan, M. and Song, A. ( 2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in-vitro. Angiogenesis 7: 335-345.
71. Wedam, S.B., Low, J.A., Yang, S.X., Chow, C.K., Choyke, P., Danforth, D. et al. (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24: 769-777.
72. Weidner, N., Folkman, J., Pozza, F., Bevilacque, P., Allred, E.N., Moore, D.H. et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887.
73. Weigand, M., Hantel, P., Kreienberg, R. and Waltenberger, J. ( 2005) Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8: 197-204.
74. Yang, S.X., Steinberg, S.M., Nguyen, D., Du, T.D., Modrusan, Z. and Swain, S.M. ( 2008) Gene expression profile and angiogenic markers correlate with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res 14: 5893-5899.
75. Zhu, X., Wu, S., Dahut, W.L. and Parikh, C.R. ( 2007) Risks for proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193.